聯絡我們
CONTACT
本平台目的為推廣台灣臨床試驗，提供廠商、研究者及一般民眾臨床試驗之相關訊息。 若您需要刊登受試者招募廣告、臨床試驗相關活動或臨床試驗受托機構訊息，歡迎留下您的資料與聯絡方式，我們會儘速跟您連繫。
若有臨床試驗設計規劃上的諮詢需求，歡迎至財團法人醫藥品查驗中心(CDE)網站的諮詢輔導專區，填寫資料後送出，會有專人與您連繫。
1. 機構及研究團隊執行細胞治療臨床試驗經驗充足
2. 擁有嚴謹的臨床試驗執行程序，確保受試者權益及安全
3. 推廣早期臨床試驗及臨床試驗繼續教育
National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry. Diabetes Ther 2015 ;6(4):519-530
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015 ;38(3):384-93
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab 2017;19(11):1610-1619
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019;393(10184):1937-1947
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2019;7(6):429-441
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-29
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383(15):1425-1435
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63